GlassScriptPhysician profile
Jensen C Stock
NPI 1851918767
$966.07
in general payments reported to CMS, 2019-2025
20 companies · $385 in 2025
The $385 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $161 · 2024: $420 · 2025: $385.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $934 · Education: $31.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $934.09 |
| Education | $31.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $168.31 | 2023-2025 | Breztri, Farxiga |
| Novo Nordisk INC | $140.51 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $112.59 | 2023-2025 | Caplyta |
| Glaxosmithkline, LLC. | $80.43 | 2023-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Exact Sciences Corporation | $65.45 | 2023-2025 | Cologuard Collection Kit |
| Corium, LLC | $45.62 | 2024 | Azstarys |
| Amgen INC. | $45.38 | 2025 | Evenity, Repatha, Prolia |
| Lilly USA, LLC | $44.63 | 2024 | Zepbound, Mounjaro, Jardiance |
| Novartis Pharmaceuticals Corporation | $34.14 | 2023-2024 | |
| Phadia US INC. | $31.50 | 2024-2025 | Immunocap |
| Otsuka America Pharmaceutical, INC. | $25.74 | 2025 | Rexulti |
| Sanofi-Aventis U.S. LLC | $24.22 | 2025 | |
| Dexcom, INC. | $24.02 | 2024 | Dexcom G6 Transmitter |
| Edwards Lifesciences Corporation | $23.47 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Pfizer INC. | $22.18 | 2024 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.99 | 2024 | Jardiance |
| Merck Sharp & Dohme LLC | $15.93 | 2024 | Vaxneuvance, Gardasil 9, Capvaxive |
| Inspire Medical Systems, INC. | $15.28 | 2024 | Inspire |
| Xeris Pharmaceuticals, INC. | $14.00 | 2024 | Gvoke Hypopen |
| Daiichi Sankyo INC. | $13.68 | 2024 | Injectafer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jensen Stock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.